Suppr超能文献

环氧化酶-2诱导EP1和HER-2/Neu依赖性血管内皮生长因子-C上调:肺腺癌淋巴管生成的新机制。

Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.

作者信息

Su Jen-Liang, Shih Jin-Yuan, Yen Men-Luh, Jeng Yung-Ming, Chang Cheng-Chi, Hsieh Chang-Yao, Wei Lin-Hung, Yang Pan-Chyr, Kuo Min-Liang

机构信息

Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan.

出版信息

Cancer Res. 2004 Jan 15;64(2):554-64. doi: 10.1158/0008-5472.can-03-1301.

Abstract

Cyclooxygenase (COX)-2, the inducible isoform of prostaglandin H synthase, has been implicated in the progression of human lung adenocarcinoma. However, the mechanism underlying COX-2's effect on tumor progression remains largely unknown. Lymphangiogenesis, the formation of new lymphatic vessels, has recently received considerable attention and become a new frontier of tumor metastasis research. Here, we study the interaction between COX-2 and the lymphangiogenic factor, vascular endothelial growth factor (VEGF)-C, in human lung cancer cells and their implication in patient outcomes. We developed an isopropyl-beta-D-thiogalactopyranoside-inducible COX-2 gene expression system in human lung adenocarcinoma CL1.0 cells. We found that VEGF-C gene expression but not VEGF-D was significantly elevated in cells overexpressing COX-2. COX-2-mediated VEGF-C up-regulation was commonly observed in a broad array of non-small cell lung cancer cell lines. The use of pharmacological inhibitors or activators and genetic inhibition by EP receptor-antisense oligonucleotides revealed that prostaglandin EP(1) receptor but not other prostaglandin receptors is involved in COX-2-mediated VEGF-C up-regulation. At the mechanistic level, we found that COX-2 expression or prostaglandin E(2) (PGE(2)) treatment could activate the HER-2/Neu tyrosine kinase receptor through the EP(1) receptor-dependent pathway and that this activation was essential for VEGF-C induction. The transactivation of HER-2/Neu by PGE(2) was inhibited by way of blocking the Src kinase signaling using the specific Src family inhibitor, PP1, or transfection with the mutant dominant negative src plasmid. Src kinase was involved in not only the HER-2/Neu transactivation but also the following VEGF-C up-regulation by PGE(2) treatment. In addition, immunohistochemical staining of 59 lung adenocarcinoma specimens showed that COX-2 level was highly correlated with VEGF-C, lymphatic vessels density, and other clinicopathological parameters. Taken together, our results provided evidence that COX-2 up-regulated VEGF-C and promotes lymphangiogenesis in human lung adenocarcinoma via the EP(1)/Src/HER-2/Neu signaling pathway.

摘要

环氧化酶(COX)-2是前列腺素H合成酶的诱导型同工酶,与人类肺腺癌的进展有关。然而,COX-2影响肿瘤进展的机制在很大程度上仍不清楚。淋巴管生成,即新淋巴管的形成,最近受到了相当多的关注,并成为肿瘤转移研究的一个新前沿。在这里,我们研究了COX-2与淋巴管生成因子血管内皮生长因子(VEGF)-C在人肺癌细胞中的相互作用及其对患者预后的影响。我们在人肺腺癌CL1.0细胞中建立了异丙基-β-D-硫代半乳糖苷诱导型COX-2基因表达系统。我们发现,在过表达COX-2的细胞中,VEGF-C基因表达显著升高,而VEGF-D基因表达没有显著变化。COX-2介导的VEGF-C上调在多种非小细胞肺癌细胞系中普遍存在。使用药理抑制剂或激活剂以及EP受体反义寡核苷酸进行基因抑制表明,前列腺素EP(1)受体而非其他前列腺素受体参与了COX-2介导的VEGF-C上调。在机制层面,我们发现COX-2表达或前列腺素E(2)(PGE(2))处理可通过EP(1)受体依赖性途径激活HER-2/Neu酪氨酸激酶受体,并且这种激活对于VEGF-C的诱导至关重要。使用特异性Src家族抑制剂PP1阻断Src激酶信号传导或转染突变型显性负性src质粒可抑制PGE(2)对HER-2/Neu的反式激活。Src激酶不仅参与了HER-2/Neu的反式激活,还参与了PGE(2)处理后随后的VEGF-C上调。此外,对59例肺腺癌标本的免疫组织化学染色显示,COX-2水平与VEGF-C、淋巴管密度及其他临床病理参数高度相关。综上所述,我们的结果提供了证据,表明COX-2通过EP(1)/Src/HER-2/Neu信号通路上调VEGF-C并促进人肺腺癌中的淋巴管生成。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验